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Smaller recombinant antibody fragments as single-domain anti-bodies (sdAbs) are emerging as credible alternatives because of 
their target specificity, high affinity, and 
cost-effective recombinant production. 
sdAbs have been forged into multivalent 
and multispecific therapeutics, or tar-
geting moieties, that are able to shuttle 
their linked therapeutic cargo (i.e., drugs, 
nanoparticles, toxins, enzymes, and 
radionuclides) to the receptor of inter-
est. Their ability to permeate across the 
blood brain barrier is receiving industrial 
interest for neurological and neuro-onco-
logical indications.
GoinG sinGle domain
Biologic therapies such as monoclonal 
antibodies (mAbs) are enabling the tar-
geted, personalized treatment of cancer, 
inflammatory diseases, infectious dis-
eases, and diseases of the central ner-
vous system. With 25 mAb products on 
the market and more than 100 undergo-
ing clinical trials (1–3), it is evident that 
engineered antibodies have come of age 
as biopharmaceuticals (4).
Intact antibodies (immunoglobulins 
IgG, IgM, IgA, and IgE) are highly spe-
cific targeting reagents that form part 
of our key defence against pathogens 
and toxins. IgG, the main serum anti-
body, the intact form of which is almost 
exclusively used in therapeutic antibod-
ies, is a Y-shaped, multidomain protein 
with antigen-binding sites located on 
the two Fab (antigen-binding fragment) 
tips and effector functions mediated 
by the stem Fc (crystallizable fragment) 
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domain (see Figure 1). Antibodies 
are bivalent, (i.e., able to bind to 
two antigens with high affinity 
and for long retention times [avid-
ity] on many cell-surface receptors 
and polyvalent antigents). There is, 
however, a range of applications for 
which the Fc-mediated effects are 
neither required nor are desirable. 
Inappropriate activation of the Fc 
receptor-expressing cells by anti-
bodies can lead to cytokine release 
and toxicity. On the other hand, 
their long circulation half-life 
results in poor contrast in imaging 
applications. 
In comparison to the inte-
gral antibody, the Fab shows an 
increased ability to penetrate dense 
tissues as solid tumors and the Fv 
[is this correct? or should it be Fc?] 
appears to be even more effective 
(5). Hence, the reduction of the 
Fabs to a monomeric domain unit, 
as VH or VL, should be, theoreti-
cally, more effective in the recogni-
tion of the associated antigen. Thus, 
dissecting IgGs initially through 
enzymatic proteolysis (i.e., with 
papain or pepsin) and later geneti-
cally engineering them into their 
constituent monovalent domains or 
bivalent fragments (Fab2, diabod-
ies, and minibodies) (see Figure 2) 
would improve their clinical value. 
Smaller recombinant antibody frag-
ments such as monovalent anti-
body fragments (Fab, scFv) and 
engineered variants (diabodies, tri-
abodies, minibodies, sdAbs) such as 
antibody-drug or antibody-nanopar-
ticle conjugates are emerging as 
credible alternatives [check sentence, 
is this correct?]. Many of these prod-
ucts are under clinical investigations 
(4) as Big Pharma and small and 
medium enterprises (SMEs) continue 
to make significant investments in 
bringing these new therapeutics 
to the market. The main drivers 
include the more economical pro-
duction and unique and superior 
properties for a range of diagnostic 
and therapeutic applications. 
Small, Stable, and  
eaSy to engineer
In the late 1980s, a sdAb was firstly 
isolated by Greg Winter’s group at 
the MRC Laboratory of Molecular 
Biology in Cambridge, UK, com-
prising only a VH domain of an 
antibody (6). It was four times 
smaller than a Fab and half of the 
size of Fv. Conventional antibod-
ies are large (150 kDa), while small 
recombinant antibodies have a 
mass range between 25–50 kDa. A 
sdAb is defined as the smallest anti-
gen-binding fragment of antibod-
ies, ranging from 11 to 15 kDa, and 
consists of a variable domain of an 
antibody VH or VL chain contain-
ing three or six naturally occur-
ring complementary determining 
regions (CDRs) that permit specific 
recognition of the antigen (7). 
The sdAbs have several benefits 
compared to other antigen-binding 
units (8). Firstly, the dAb [should 
this be sdAb?] are antibody-derived 
fragments that can be expressed 
in bacteria as active, soluble, and 
robust proteins. Additionally, sin-
gle variable domains are known to 
be able to potentially target cryptic 
epitopes that are poorly accessi-
ble to intact antibodies but enable 
pathogen to bind to their target 
receptors (6, 9). Nevertheless, their 
use was originally limited because 
single variable domains rarely 
retained the affinity of the par-
ent antibody and were also poorly 
soluble and prone to aggregation. 
The discovery that camelids 
(camels and llamas) and cartilagi-
nous fish (wobbegong and nurse 
sharks) evolved into high-affinity, 
single, V-like domains (called VhH 
in camelids and V-NAR in sharks), 
mounted on an Fc-equivalent con-
stant domain, is a crucial compo-
nent of their immune response 
(8, 10–13) has resulted in trans-
lation of these camel, llama, and 
shark sdAbs into novel therapeu-
tics [sentence doesn’t make sense, 
please rephrase]. Camelid VhH 
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Figure 1: Immunoglobulins basic structure. 
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and shark V-NAR domains display 
long surface loops, often larger 
than human antibodies and are 
able to penetrate cavities in tar-
get antigens (14). They are, in gen-
eral, soluble and can be produced 
as stable in-vitro targeting reagents 
for sensitive diagnostic platforms 
and nanosensors (14–17). However, 
for in-vivo administration, immu-
nogenicity concerns require their 
humanization even though llama 
VhH domain have been claimed to 
be only minimally immunogenic 
(18). Thus, human single domains 
would be preferable for in-vivo 
applications provided problems of 
poor stability and solubility can be 
overcome. 
Crystal and solution structures 
of several sdAbs adopt a β-sheet 
structure similar to a VH or VL 
immunoglobulin fold in a con-
ventional antibody. sdAbs have 
similar affinity to antigens as 
whole antibodies, but are more 
heat-resistant and stable towards 
detergents and high urea concen-
trations. Those derived from cam-
elid and fish antibodies are less 
lipophilic and better soluble in 
water, owing to their complemen-
tary determining regions (CDR3) 
that form an extended loop cov-
ering the lipophilic site the nor-
mally binds to a light chain (19, 
20). Examples include the came-
lid-origin nanobodies that consist 
of a single variable domain and 
two constant domains CH2 and 
CH3 (Ablynx). In contrast to com-
mon antibodies, two out of six 
sdAb survived a temperature of 90 
°C without losing their ability to 
bind antigens (21), a property that 
is attributed to a reversible unfold-
ing behavior (7). Stability towards 
gastric acid and proteases depends 
on the amino-acid sequence. 
Some species have been shown 
to be active in the intestine after 
oral application, but their low 
absorption from the gut impedes 
the development of systemically 
active sAbs (22–26). The compara-
tively low molecular weight leads 
to a better tissue permeability, but 
also to short plasma half-lives and 
renal excretion (22). 
Production of stable, high-affin-
ity mAb fragments in high yield 
for preclinical and clinical trials 
can be a serious bottleneck in the 
product pipeline. Identification 
and design of mutations that min-
imize the hydrophobic interface 
and direct selection from phage 
libraries have contributed greatly 
towards overcoming solubility 
and stability problems (18–21). 
Bacteria are favored for expression 
of V-like domains, while human 
sdAbs can be expressed at high 
yields (> 50 mg L-1 in Escherichia 
coli and > 0.5 g L-1 in Pichia pas-
toris shaker f lask cultures) (4). 
Nevertheless, several strategies are 
developed to improve recombi-
nant expression such as the use 
of terminal polypeptides (e.g., 
c-Myc, histidine, and the “flag” 
epitope, DYKDDDK) to enhance 
affinity purification after expres-
sion into the periplasm of E. coli 
(4). Immunogenicity concerns in 
relation to these strategies are still 
under investigation by drug regu-
latory agencies. Favorable prop-
erties, such as good expression, 
thermal stability, and solubility, 
are co-selected with binding activ-
ity using phage libraries, such as 
in the case of human VH domain 
antibodies (21), a method that 
enables also cost-effective produc-
tion (see Table I). 
Given their high affinity and 
specificity, the small size of dAbs 
might make them particularly 
suitable for targeting antigens 
in obstructed locations, such as 
tumors where penetration into 
poorly vascularized tissue is cru-
cial to the success of the drug (7). 
The delivery of toxins or radio-
isotopes to diseased tissues would 
be another ideal function for a 
dAb, which could provide specific 
delivery of the toxin to the tumor 
while minimizing the length of 
time that the toxin could cause 
damage to healthy cells in the 
blood (7). The short half-life of 
dAbs is well suited to applications 
in which rapid clearance is essen-
tial. 
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Figure 2: Schematic representation of different antibodies formats.
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Single-DomAin AntiboDieS with 
long circulAtion hAlf-life
For some applications such as treat-
ment of brain disorders, rheuma-
toid arthritis, or cancers, the target 
antigens need to be available for 
binding in the bloodstream for a 
prolonged time requiring a pro-
longed serum half-life to increase 
time that the antibody has to act 
on its target and to reduce the 
frequency of administration (7). 
PEGylation, conjugation, or fusion 
to serum albumin, and fusion to 
either the Fc or complete anti-
body constant regions (7) have 
been employed; however, the latter 
method can lead to complement 
activation.
PEGylation increases the appar-
ent hydrodynamic size of the 
antibody fragment above the glo-
merular clearance limit, thereby 
improving its circulating half-
life, while also improving solu-
bility, enhancing bioavailability 
by reducing losses at subcutane-
ous injection sites, and reducing 
immunogenicity and toxicity of 
therapeutic proteins (7). For exam-
ple, conjugation of small human V 
domains (11–15 kDa) with a single 
PEG molecule extends the half-life 
from the normally rapid half-life 
of 20 minutes to 39 hours in mice 
(4). The site of modification needs 
to be carefully selected to ensure 
it does not interfere with the anti-
gen-binding site. 
Conjugation/l inkage of the 
sdAb fragment to a protein that 
has a naturally extended serum 
half-life protein like serum albu-
min is another method to pro-
long serum half-life of sdAbs. 
Site-specific conjugation of a Fab 
fragment to serum albumin by 
maleimide crosslinking or gen-
eration of a bispecific Fab with 
specificity for serum albumin 
in one arm increased half life in 
rats (27). Fusion of peptides with 
high affinity for serum albumin 
to an anti-tissue factor Fab lead to 
37-fold and 26-fold extension in 
rabbit and mouse serum half-life, 
respectively (7). Albumin is also 
known to accumulate in tumors 
(28) and in arthritic joints, poten-
tially enabling a further level of 
targeting in disease specific situa-
tions (29). A range of human sdAbs 
isolated by phage display that 
bind to mouse, rat, and/or human 
serum albumin were produced that 
have half-lives that match the half-
life of serum albumin (~19 days) 
(AlbudAbs) compared to a termi-
nal half-life of non-serum albumin 
binding dAbs of less than 45 min-
utes (29). The fusion of an Albu/Ab 
to interleukin-1 receptor antago-
nist (AlbudAb/IL-1ra) resulted in 
improved in-vivo efficacy due to 
its extended serum half-life (29). 
AlbuAbs could be used to generate 
a range of long half-life versions 
of many drugs (such as metho-
trexate, interferon alpha, pep-
tide antagonists of TNFa) (13) to 
reduce frequency of administra-
tion and improve clinical profiles 
(Domantis-GSK, Phase I clinical 
trials, PN0621).
therApy AnD DiAgnoSiS of  
brAin DiSeASeS with SDAbS 
Due to prolonged aging, the prev-
alence of neurological disorders 
is growing, placing neurological 
disorders as a public health pri-
ority and an important cause of 
mortality constituting 12% of total 
deaths globally (30). The capillaries 
of the brain have evolved to con-
strain the movement of molecules 
and cells between the blood and 
brain, providing a natural defence 
against circulating toxic or infec-
tious agents but also an effective 
barrier to drug delivery excluding 
98% of therapeutic drugs. The rela-
tive impermeability of the blood 
brain barrier (BBB) results from 
tight junctions between capillary 
endothelial cells that are formed 
by cell-adhesion molecules, high 
expression of active efflux trans-
port proteins, and large densities 
of mitochondria within endothe-
lial cells (31). Thus, nearly all large 
molecules (molecular weight >1 
kDa) such as recombinant proteins 
or gene-based medicines are unable 
to cross the BBB. 
Conventional antibodies are 
unable to cross the BBB. Antibodies 
(and other peptides, proteins, 
and nucleic acids), however, have 
been shown to be able to be trans-
ported across by binding to recep-
tors selectively expressed on brain 
capillary endothelial cells such 
as transferrin or the insulin-like 
growth factor (IGF-1) by receptor-
mediated endocytosis (32). An 
alternative strategy for enhancing 
their transport relied on adsorp-
Table I: Selected novel antibody fragments in development.
Molecule Company Target Antigen Indications
Nanobodies  
(heavy-chain camelid 
antibodies)
Ablynx Von Willebrand factor 
(vWF),  
tumor necrosis factor 
alpha (TNFα), others
Thrombosis, rheumatoid 
arthritis, inflammatory bowel 
disease, oncology, immune 
disorders, Alzheimer’s disease
Domain antibodies 
(heavy- or light-chain 
human antibodies)
GSK (Domantis 
prior to Dec 2006)
TNFα/TNF1R (tumor 
necrosis factor 1 
receptor) CD40, IL13/
IL4, other unspecified
Rheumatoid arthritis, 
Crohn’s disease, chronic 
obstructive pulmonary disease, 
autoimmune disease, asthma, 
oncology
Shark antibodies 
(shark IgNAR)
Wyeth (Haptogen 
prior to Oct 2007)
Unspecified Infectious diseases, oncology, 
inflammation
Unibodies (modified 
human IgG4)
Genmab Unspecified Oncology, autoimmune / 
inflammatory conditions
Ig = immunoglobin, NAR = new antigen receptor, IL = interleukin.
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tive-mediated endocytosis of cat-
ionized antibodies prepared by 
conversion of the surface carboxyl 
groups of the antibody to amino 
groups (33–35). However, even if 
an antibody is able to permeate the 
BBB, it will likely be the target of 
brain endothelial cell metabolism. 
Thus, the stability advantages of 
sdAbs (e.g., high expression lev-
els, high affinity, high solubility, 
small size, and good intracellular 
stability) make them ideal for cen-
tral nervous system therapeutic or 
imaging applications (see Table I). 
Ablynx (Ghent, Belgium) is 
focused on the discovery and devel-
opment of sdAbs, the nanobod-
ies for a range of human diseases 
including inflammation, throm-
bosis, oncology, and neurology 
with seven sdAb products in the 
clinic (three in Phase II and four 
in Phase III) (36, 37). BI 1034020 
Nanobody is being developed in 
collaboration with Boehringer 
Ingelheim for Alzheimer’s disease 
and, currently, is undergoing Phase 
I studies. Bi-paratopic humanized 
half-life extended anti-aβ VhH were 
shown to be able to bind to two dif-
ferent epitopes on the free aβ pep-
tide (N-terminus and central) with 
an extremely high affinity (≤ 1pM), 
reducing aβ levels in plasma in a 
preclinical model for Alzheimer’s 
disease (amyloid precursor protein 
[APP] transgenic mice) (38), which 
is associated with prevention of 
amyloid plaque formation in the 
brain and clearance of existing 
plaques (37). Ablynx is collaborat-
ing with Merck and Merck Serono 
to co-develop other sdAbs for neu-
rological or neuro-oncological indi-
cations. 
Transport across the BBB in 
human brain endothelial cells has 
been reported for llama sdAbs (39, 
40). Using a llama sdAb phage dis-
play library (41), a new antigen-
ligand system was identified for 
transvascular brain delivery (42). 
In-vitro and in-vivo studies have 
been reported focused on the devel-
opment of two sdAbs, FC5 and 
FC44 (39, 43, 44), which selectively 
recognized human cerebrovascular 
endothelial cells and transmigrated 
across the BBB. The transport of 
FC5 and FC44 across the human 
brain endothelial cells is polarized, 
charge-independent, and tempera-
ture-dependent, suggesting a recep-
tor-mediated process. 
Abulrob et al. demonstrated that 
the transcytosis of FC5 is depen-
dent on clathrin-coated vesicles 
and on the recognition of specific 
oligosaccharide antigenic epitopes 
on the surface of the human endo-
thelial cells (39, 40). Following 
the internalization, FC5 was tar-
geted to early endosomes, bypassed 
late endosomes/lysosomes, and 
remained intact after the trans-
cytosis. FC5 failed to recognize 
brain-endothelial cells-derived lip-
ids suggesting that it binds luminal 
α(2,3)-sialoglycoprotein receptor, 
which triggers clathrin-mediated 
endocy tosi s  (39).  Moreover, 
Abulrod et al. also described the 
modification of the FC5 dAb with 
a horseradish peroxidase (HRP)-
tagged IgG to improve its potential 
as a BBB carrier vector (40). Briefly, 
a free cysteine was engineered at 
the C-terminal of FC5, 17 amino-
acid residues distant from the 
antigen-binding site. The cysFC5 
maintained the transmigration abil-
ity across an in-vitro BBB model. 
The cysteine group was used fur-
ther to attach the HRP-IgG (~190 
kDa). It was shown that only HRP-
IgG conjugated to the FC5 trans-
migrated across the in-vitro BBB 
model, suggesting that cysFC5 is 
able to transport larger molecules 
into the target tissue. The receptor 
has been identified, and is related 
to a novel isoform of the transmem-
brane domain protein 30A (TMEM 
30A) (31). TMEM30A is also known 
as CDC50A, which is responsible 
for the cell surface expression of 
ATP8B1 (hypothesized to be a flip-
pase for phospatidylserine). FC5 
is now being developed to deliver 
therapeutic amounts of doxorubi-
cin to the brain after pentameriza-
tion and association to PEGylated 
liposomes (31). Functionalization 
of nanoparticles with sdAb such 
as FC5 increases their valency, as 
multiple number of antibodies can 
be conjugated to the nanocarriers 
by spontaneous binding of the his-
tidine tag of the antibody to the 
nitrilotriacetic acid (NTA) of the 
lipid. After intravenous administra-
tion (8.9 mg kg-1), brain levels of 
FC5-targeted, doxorubicin-loaded, 
PEGylated liposomes were increased 
(~0.6 µcg g-1 brain, double those 
achieved by doxorubicin-loaded, 
PEGylated liposomes). The pentam-
eric form of FC5 (P5) displays better 
Single-Domain Antibodies
Table II: Selected single-domain antibodies (sdAbs) for brain targeting and neurological disorders.
Application sdAb Target Outcomes Reference
Drug delivery
HRP-IgG-cysFC5 TMEM30A Significant transcellular migration in an in vitro blood brain barrier model. (40)
P5-Doxorubicin-loaded 
PEGylated liposomes TMEM30A
Double brain levels obtained with doxorubicin-loaded PEGylated liposomes 
(~0.15% of intravenously injected dose). (45)
Nanobody ALX-0081 A1 domain of vWF
ALX-0081 prevented middle cerebral artery thrombosis and induced 
reperfusion when given immediately and 15 minutes after complete 
occlusion and reduced brain damage without inducing hemorrhage.
(46)
HRP = horseradish peroxidase, vWF = von Willebrand factor 
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binding to brain endothelial cells 
and is more efficiently transcytosed 
across brain endothelial cells than 
the monomeric form and is co-
localized with neurons in brain tis-
sue (see Table II). 
ALX-0081, a nanobody against 
the A1 domain of von Willebrand 
factor (VWF) that blocks VWF 
binding to main platelet receptor 
glycoprotein (GPIb), was compared 
with thrombolytic agent recombi-
nant tissue plasminogen activator 
(rtPA) and tirofiban (glycoprotein 
IIb/IIIa inhibitor, antiplatelet agent) 
in a middle cerebral artery (MCA) 
guinea pig thrombosis model. 
ALX-0081 prevented MCA throm-
bosis and induced reperfusion 
when given immediately and 15 
minutes after complete occlusion 
and reduced brain damage with-
out inducing hemorrhage, whereas 
tirofiban prevented thrombosis 
but did not induce reperfusion and 
induced striking brain hemorrhage. 
rtPA also induced reperfusion when 
given 60 minutes after occlusion 
but provoked brain hemorrhage (see 
Table II). Skin bleeding time was not 
modified or was moderately pro-
longed by ALX-0081, whereas tiro-
fiban and rtPA prolonged it. Thus, 
the inhibition of the GPIb–VWF 
axis by nanobodies in guinea pigs 
prevented cerebral artery thrombo-
sis and induced early reperfusion 
without provoking intracerebral 
bleeding, hence, reducing brain 
infarct area; ALX-0081 administra-
tion, early after onset of an acute 
stroke, may induce revascularisa-
tion and reduce brain damage with 
less haemorrhagic risk than rtPA.
ConCluSion
After a decade of intensive engi-
neering followed by preclinical 
and clinical testing, antibody frag-
ments joined mAbs as powerful 
therapeutic agents particularly for 
targeting cancer, inflammatory, 
autoimmune, and viral diseases. 
With recent advances in scaffold 
design, construction, and selection 
methodologies, there is now a rapid 
process for recombinant synthesis 
of specific, high-affinity antibody 
fragments against virtually any tar-
get. sdAbs are able to penetrate anti-
gen clefts (e.g., enzyme active sites, 
cell surface receptors) targeting 
both antigens and immunosilent 
epitopes. sdAbs have shown impres-
sive tumor-to-blood ratios and are 
increasingly applied towards the 
discovery of new cancer or inflam-
matory biomarkers and nano-
sensors while they are currently 
explored as highly refined biophar-
maceutical drugs in challenging 
therapeutic areas such as neurology 
and oncology. 
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